Trials / Recruiting
RecruitingNCT06906874
Activated Charcoal Use in Chronic Kidney Disease Patients
Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Mansoura University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Conditions
- End Stage Renal Disease (ESRD)
- CKD 5D, Hemodialysis
- CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Activated Charcoal | oral activated charcoal capsules |
| DRUG | Phosphate Binders | calcium-based or non-calcium based (sevelamer) binders |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2025-04-02
- Last updated
- 2025-08-08
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06906874. Inclusion in this directory is not an endorsement.